Mycoses in Pediatric Patients

Infectious Disease Clinics of North America

Volumn 20, Issue 3, 2006, Pages 663-678

  Steinbach, William J ^a   Walsh, Thomas J ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; BILIRUBIN; CASPOFUNGIN; CYCLODEXTRIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; PLACEBO; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; BLURRED VISION; CANDIDIASIS; CHILD; CHILDHOOD DISEASE; DIARRHEA; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INFUSION; LIVER DYSFUNCTION; MYCOSIS; NAUSEA; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; RASH; REVIEW; VOMITING;

ANTIFUNGAL AGENTS; CHILD; HUMANS; MYCOSES;

EID: 33748710296     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.06.006     Document Type: Review

References (75)

1. Pfaller M.A., Diekema D.J., Jones R.N., et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40 (2002) 852
2. Krupova Y., Sejnova D., Dzatkova J., et al. Prospective study on fungemia in children with cancer: analysis of 35 cases and comparison with 130 fungemias in adults. Support Care Cancer 8 (2000) 427
3. Pasqualotto A.C., Nedel W.L., Machado T.S., et al. A 9-year study comparing risk factors and the outcome of paediatric and adults with nosocomial candidaemia. Mycopathologia 160 (2005) 111
4. Benjamin D.K.J., Garges H., and Steinbach W.J. Candida bloodstream infection in neonates. Semin Perinatol 27 (2003) 375
5. Benjamin D.K.J., Stoll B.J., Fanaroff A.A., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117 (2006) 84
6. Benjamin D.K.J., Poole C., Steinbach W.J., et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112 3 Pt 1 (2003) 634
7. Steinbach W.J. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 24 (2005) 358
8. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001 (1824) 33
9. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408
10. Walmsley S., Devi S., King S., et al. Invasive Aspergillus infections in a pediatric hospital: a ten year review. Pediatr Infect Dis J 12 (1993) 673
11. Abbasi S., Shenep J.L., Hughes W.T., et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 29 (1999) 1210
12. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240
13. Herbrecht R., Auvrignon A., Andres E., et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 20 (2001) 77
14. Gefter W.B., Albelda S.M., Talbot G.H., et al. Invasive pulmonary aspergillosis and acute leukemia: limitations in the diagnostic utility of the air crescent sign. Radiology 157 (1985) 605
15. Thomas K.E., Owens C.M., Veys P.A., et al. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 33 (2003) 453
16. Allan B.T., Patton D., Ramsey N.K.C., et al. Pulmonary fungal infections after bone marrow transplantation. Pediatr Radiol 18 (1988) 118
17. Taccone A., Occhi M., Garaventa A., et al. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 23 (1993) 177
18. Sulahian A., Tabouret M., Ribaud P., et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 15 (1996) 139
19. Herbrecht R., Letscher-Bru V., Oprea C., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 7 (2002) 1898
20. Verweij P.E., Weemaes C.M., Curfs J.H.A.J., et al. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 38 (2000) 3900
21. Walsh TJ, Schaufele RL, Sein T, et al. Reduced expression of galactomannan antigenemia in patients with invasive aspergillosis and chronic granulomatous disease or Job's syndrome. Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, October 24-27, 2002.
22. Groll A.H., Piscitelli S., and Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug. Adv Pharmacol 44 (1998) 343-500
23. Steinbach W.J., and Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37 Suppl 3 (2003) S157
24. Walsh T.J., Viviani M.A., Arathoon E., et al. New targets and delivery systems for antifungal therapy. Med Mycol 38 (2000) 335
25. Walsh T.J., Goodman J.L., Pappas P., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerate dose study. Antimicrob Agents Chemother 45 (2001) 3487
26. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad trial). 47th American Society of Hematology Annual Meeting, Atlanta, GA, October 10-13, 2005.
27. Anak S. Safety and efficacy of AmBisome in patients with fungal infections. A post marketing multicentre surveillance study in Turkey. In: Focus on fungal infections 14. New Orleans, LA, March 24-26, 2004.
28. Dismukes W.E. Introduction to antifungal agents. Clin Infect Dis 30 (2000) 653
29. Dix S.P., and Andriole V.T. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 20 (2000) 1
30. Graybill J.R., Tollemar J., Torres-Rodriguez J.M., et al. Antifungal compounds: controversies, queries and conclusions. Med Mycol 38 (2000) 323
31. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383
32. Wong-Beringer A., Jacobs R.A., and Guglielmo B.J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27 (1998) 603
33. Leenders A.C.A.P., Daenen S., Jansen R.L.H., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103 (1998) 205
34. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for the treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359
35. Linder N., Klinger G., Shalit I., et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B products. J Antimicrob Chemother 52 (2003) 663
36. Walsh T.J., Whitcomb P., Piscitelli S., et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 41 (1997) 1944
37. Würthwein G., Groll A.H., Hempel G., et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 49 (2005) 5092
38. Walsh T.J., Seibel N.L., Arndt C., et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18 (1998) 702
39. Scarcella A., Pasquariello M.B., Guigliano B., et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 17 (1998) 146
40. Weitkamp J.H., Poets C.F., Sievers R., et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 26 (1998) 11
41. Sandler E.S., Mustafa M.M., Tkaczewski I., et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 22 (2000) 242
42. Al Arishi H., Frayha H.H., Kalloghlian A., et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 15 (1998) 643
43. Lee J.W., Seibel N.I., Amantea M.A., et al. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 120 (1992) 987
44. Brammer K.W., and Coates P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 13 (1994) 325
45. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33 (1997) 52
46. Vscoli C.E., Castagnola M., Fioredda B., et al. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 35 (1991) 365
47. Novelli V., and Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 43 (1999) 1955
48. Fasano C., O'Keeffe J., and Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 13 (1994) 325
49. Huttova M., Hartmanova I., Kralinsjy K., et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 17 (1998) 1012
50. Driessen M., Ellis J.B., Cooper P.A., et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 15 (1996) 1107
51. Kaufman D., Boyle R., Hazen K.C., et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 345 (2001) 1660
52. Kaufman D., Boyle R., Hazen K.C., et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 147 (2005) 172
53. de Repentigny L., Ratelle J., Leclerc J.-M., et al. Repeated-dose pharmacokinetic of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 42 (1998) 404
54. Schmitt C., Perel Y., Harousseau J.L., et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother 45 (2001) 1561
55. Groll A.H., Wood L., Roden M., et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46 (2002) 2554
56. Chariyalertsak S., Supparatpinyo K., Sirisanthana T., et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 34 (2002) 277
57. Walsh T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48 (2004) 2166
58. Walsh TJ, Driscoll T, Groll A, et al. Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
59. Ullmann A.J., Cornely O.A., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 (2006) 658
60. Krishna G, Wexler D, Courtney R, et al. Posaconazole plasma concentrations in pediatric patients with invasive fungal infections. Program of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
61. Segal B.H., Barnhart L.A., Anderson V.L., et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 40 (2005) 1684
62. Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole experience in the treatment of zygomycosis. Program and Abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
63. Walsh T.J., Adamson P.C., Seibel N.L., et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 49 (2005) 4536
64. Lehrnbecher T, Attarbaschi A, Schuster F, et al. Caspofungin in immunocompromised pediatric patients without therapeutic alternative: a multicenter survey. Program of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
65. Odio C.M., Araya R., Pinto L.E., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 23 (2004) 1093
66. Natarajan G., Lulic-Botics M., Rongkavilt C., et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 25 (2005) 770-777
67. Heresi GP, Gerstmann DR, Blumer JL, et al. Pharmacokinetic study of micafungin in premature neonates. Pediatric Academic Society Meeting, Seattle, WA.
68. Seibel N.L., Schwartz C., Arrieta A., et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49 (2005) 3317
69. Townsend R, Bekersky I, Buell DN, et al. Pharmacokinetic evaluation of echinocandin FK463 in pediatric and adult patients. Focus on Fungal Infections 11. Washington, DC.
70. Ratanatharathorn V, Flynn P, Van Burik JA, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Program and abstracts of the American Society of Hematology 44th Annual Meeting, Philadelphia, December 6-10, 2002.
71. Suleiman J, Della Negra M, Llanos-Cuentas A, et al. Open label study of micafungin in the treatment of esophageal candidiasis. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September 27-30, 2002.
72. Ullmann AJ, Van Burik JA, McSweeney P, et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis in adults and children. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003.
73. Ostrosky-Zeichner L, Anaissie E, Kontoyannis D, et al. Micafungin, an echinocandin antifungal agent for the treatment of new and refractory candidemia. Focus on fungal infections 13. Maui, HI, March 19-21, 2003.
74. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407
75. Benjamin D.K.J., Driscoll T., Seibel N.L., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50 (2006) 632